Abstract:
A control device for a switched reluctance motor includes: a switching controller configured to execute switching control to switch drive control of the switched reluctance motor between a first control mode for reducing torque fluctuations and a second control mode for reducing fluctuations of a radial force based on rotational speed and a torque of the switched reluctance motor; a first controller configured to execute first control to cause an excitation current with a current waveform for reducing the torque fluctuations to flow through the coils; and a second controller configured to execute second control to cause an excitation current with a current waveform for reducing the radial force fluctuations to flow through the coils.
Abstract:
An optical interferometer includes: a light source that emits a coherent first beam and a second beam that has a frequency difference corresponding to the natural frequency of a target molecule; amplitude modulating means that modulates the amplitude of the second beam; splitting means that splits the first beam into a reference beam and a first applied beam; optical path length adjusting means that adjusts the optical path length of the reference beam; and detecting means that detects an interference pattern between the reference beam and the first beam (a signal beam) that has experienced a stimulated Raman loss or gain in accordance with the amplitude modulation as a result of the frequency difference resonating with the target molecule when the first applied beam and a second applied beam (the amplitude modulated second beam) have been applied to a measurement position of an object.
Abstract:
The purpose of the present invention is to provide an anticancer agent for potentiating an antitumor effect, alleviating side effects, and further extending the survival rate by concomitant use with a component having an anticancer effect. An anticancer agent combining arctigenin and a component other than arctigenin that has an anticancer effect, in which the anticancer agent may be a combination drug or may be a kit configured from a formulation containing arctigenin and a formulation containing a component that has an anticancer effect, and the concomitant use of arctigenin and the component having an anticancer effect more strongly inhibits tumor growth and reduces the proportion of cancer stem cells in the tumor, making it possible to extend the total survival time and to alleviate side effects caused by the component having an anticancer effect.
Abstract:
The present invention provides a method for detecting an interaction, which method can solve not only the problem of false negatives but also the problem of false positives. This method is a method for detecting a protein(s) that interact(s) with a target substance(s), the method comprising repeating a (1) transcription step, (2) assignment step, (3) selection step, and (4) amplification step, wherein: (a) in each of a plurality of times of preparation of a cDNA library among the initial preparation of a cDNA library and the round(s) of preparation of a cDNA library in the later amplification step(s), the cDNA library is prepared using a primer(s) having a sequence(s) specific to the time of preparation; (b) the cDNA libraries prepared using the primers having sequences specific to the times of preparation are mixed, and sequences in the cDNA library mixture are determined; (c) the determined sequences are subjected to measurement of the number(s) of molecules encoding the same candidate protein(s) for each time of preparation based on the sequence(s) specific to the time of preparation; and (d) a candidate protein(s) encoded by a molecule(s) that significantly increase(s) as the preparation rounds proceed is/are detected as the protein(s) that interact(s) with the target substance(s).
Abstract:
An amplifying circuit according to an embodiment includes a sample and hold circuit, an operational amplifier, a feedback capacitance, and a level shift circuit. The sample and hold circuit includes a sampling capacitance to sample an analog input signal in a sampling phase. The operational amplifier amplifies and outputs the analog input signal held by the sampling capacitance in the amplifying phase. The feedback capacitance is connected between the input terminal of the operational amplifier and the analog output terminal. The level shift circuit includes a level shift capacitance to sample the analog input signal in the sampling phase. A plurality of level shift capacitances is provided and connected in cascade between the output terminal of the operational amplifier and the analog output terminal.
Abstract:
A positive electrode-active material is provided for use in a positive electrode for a sodium secondary cell and a sodium secondary cell. Also provided is a positive electrode for a sodium secondary cell and a sodium secondary cell having a high energy density. The positive electrode-active material for a sodium secondary cell includes a composite metal oxide, which has an α-NaFeO2 type crystal structure and is denoted by Formula (1) described below: Naa(FewNixMny-zTiz)O2 (1), wherein a is greater than or equal to 0.6 and less than or equal to 1.0, w is greater than 0 and less than 0.5, x is greater than 0 and less than 0.5, y is greater than 0.03 and less than or equal to 0.5, z is greater than or equal to 0.03 and less than 0.5, and w+x+y=1.0, and y>z.
Abstract translation:提供了用于钠二次电池和钠二次电池的正极中使用的正极活性物质。 还提供了一种钠二次电池用正极和能量密度高的钠二次电池。 钠二次电池用正极活性物质包括具有α-NaFeO 2型晶体结构的复合金属氧化物,由下述式(1)表示:Naa(FewNixMny-zTiz)O 2(1),其中, 大于或等于0.6且小于或等于1.0,w大于0且小于0.5,x大于0且小于0.5,y大于0.03且小于或等于0.5,z为 大于或等于0.03且小于0.5,且w + x + y = 1.0,y> z。
Abstract:
A sodium transition metal cathode material for a rechargeable sodium battery having a P2 layered bronze crystal structure, comprising at least 55 mol % manganese, wherein the manganese valence state is at least 3.75. The material undergoes a structural transformation to a secondary cathode material by extraction of sodium during the 1st charge of a rechargeable sodium battery comprising the sodium cathode material. The material has either a composition NaxMO2 where M=Mn1-y-zLiyAz where z
Abstract:
A power generator includes a power generating unit and at least one of a power storage unit or an output unit that is electrically connected to the power generating unit. The power generating unit includes an electret having a first charged surface and a second charged surface that are charged with opposite polarities, a first electrode formed on the first charged surface, and a second electrode formed on the second charged surface. The electret is formed by polarizing an electret material that includes an inorganic dielectric having a bandgap energy of 4 eV or more. At least one of the first electrode or the second electrode are partially disposed on the corresponding charged surface such that at least one of the first charged surface or the second charged surface has a portion as a current collecting surface exposed outward.
Abstract:
A glycosylated neuropeptide derivative, having a neuropeptide sequence, a cell-penetration accelerating sequence, an endosomal-escape accelerating sequence, and a sugar chain.
Abstract:
A non-human animal or a part of the same in which the function of Mipep gene is totally or partially lost in adipose tissues or the expression level of Mipep gene in adipose tissues is lowered compared to a wild type; and mesenchymal stem cells or adipocytes in which the function of Mipep gene is totally or partially lost or the expression level of Mipep gene is lowered compared to a wild type. A therapeutic or prophylactic drug that includes the mesenchymal stem cells or adipocytes or a culture supernatant thereof; and a method for preparing a mitokine mixture using the non-human cells, mesenchymal stem cells or adipocytes.